|
The Research Institute for Children facilitates the development
of marketable products or processes from new research discoveries
and the distribution of those products or processes through successful
business ventures.
TECHNOLOGY DEVELOPMENT PROGRAM
------------------------------------------------------------------------
The mission of The Research Institute for Children (RIC) is to
combine the latest science and technology with conventional medical
practice to discover more effective ways to prevent and treat
childhood diseases. With its close proximity to Children’s
Hospital, the region’s only full-service medical center
exclusively for children, the RIC benefits from the ease at which
research efforts can be transferred from the bench to the bedside.
The Technology Development Program provides
the processes and/or infrastructure required to move a research
concept or technology from the research phase to the marketplace.
This Program supports:
Advancement of RIC faculty research results
toward full commercialization by promoting industry liaisons;
and Advancement of outside research when considered consistent
with RIC’s mission and a benefit to the RIC research program.
RIC Technologies in Development
------------------------------------------------------------------------
FACULTY RESEARCH
Treatment of group B streptococcal disease with anti-GBS monoclonal
antibodies (Pincus)
Treatment of Candida infection with monoclonal antibodies (Cutler)
Rapid antifungal susceptibility assay (Cutler)
Micropipettor that monitors loading (Cutler)
Candida cell wall proteins as conjugate partners for a mannan
vaccine against candidiasis (Cutler)
A Method for affinity maturation and selection of high affinity
monoclonal antibodies (Pincus and Cutler)
Method and system for diagnosing and monitoring diabetes based
on assessment of hemoglobin glycation phenotype (Hempe)
Norion Diagnostic Innovations,
Inc.
------------------------------------------------------------------------
Norion Diagnostic Innovations, Inc. is
a start-up biotechnology company founded by Dr. Seth Pincus and
located at RIC. The company’s research is presently funded
by a phase II STTR award from the National Institutes of Health
entitled “HIV Infectivity Test for Antiviral Susceptibility”.
Norion technologies available for licensing and/or partnering
include:
Phenotypic HIV antiviral resistance
Preclinical in vitro and in vivo anti-HIV drug discovery
Anti-HIV immunotoxins
Gene-based anti-HIV drugs
Partnering with RIC
------------------------------------------------------------------------
OPTIONS
A variety of options are available for partnering with RIC including,
but not limited to:
Licensing Agreement
Research Agreement or Grant with licensing options
For More Information Contact
------------------------------------------------------------------------
Seth H. Pincus, M.D.
Children’s Hospital
200 Henry Clay Avenue
New Orleans, LA 70118
(504) 896-2700
Fax: (504) 896-2720
Email:
spincus@chnola-research.org
|
